At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INTS Intensity Therapeutics, Inc.
Trading 03-28 13:24:25 EDT
2.02
+0.03
+1.51%
| High2.03 | Low1.92 | Vol4.00K |
| Open1.97 | D1 Closing1.99 | Amplitude5.56% |
| Mkt Cap30.67M | Tradable Cap12.55M | Total Shares15.18M |
| T/O7.95K | T/O Rate0.06% | Tradable Shares6.21M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Dow Jones · 03-13
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("Invincible-3 Study") Following Periodic Review
THOMSON REUTERS · 01-28
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR Newswire · 01-28
Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5
THOMSON REUTERS · 01-13
Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6
THOMSON REUTERS · 01-10
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
PR Newswire · 01-10
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares
MT Newswires Live · 2024-12-13
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
MT Newswires Live · 2024-12-12
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
TIPRANKS · 2024-12-12
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
PR Newswire · 2024-12-12
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.
TIPRANKS · 2024-11-21
BRIEF-Intensity Therapeutics Announces Pricing Of $3 Million Registered Direct Offering And Concurrent Private Placement
Reuters · 2024-11-21
Intensity Therapeutics Inc - to Issue 1,237,113 Shares at $2.425 per Share
THOMSON REUTERS · 2024-11-21
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
THOMSON REUTERS · 2024-11-21
Press Release: Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Dow Jones · 2024-11-21
Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma
TIPRANKS · 2024-11-18
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
PR Newswire · 2024-11-18
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
THOMSON REUTERS · 2024-11-13
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 2024-11-11
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
PR Newswire · 2024-11-08
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Introduction
Company Name.
Intensity Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App